Latest News and Press Releases

Toronto, Ontario, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Toronto, Canada — January 14, 2026 A new randomized, double-blind, sham-controlled clinical trial reports that a non-invasive, home-based...

PridCor Therapeutics advances its SHIELD Long COVID study with a peer-reviewed publication and FDA confirmation of IND exemption.

CHICAGO, IL, Dec. 23, 2025 (GLOBE NEWSWIRE) -- A treatment once reserved for scuba divers is gaining attention for its potential in treating a variety of ailments, including traumatic brain...

This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk...

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European...

Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of...

TUSCALOOSA, Ala., Sept. 23, 2025 (GLOBE NEWSWIRE) -- PridCor Therapeutics today announced that Dr. David Putrino, principal investigator of the company’s SHIELD Study, participated in a national...

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral...

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services...

PridCor reports Long COVID case series: combo of valacyclovir, celecoxib & Paxlovid® shows significant, lasting symptom improvement.